Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Findings from a large Asian chronic hepatitis C real-life study
Authors: Seng Gee Lim
Wah Wah Phyo
Samir R. Shah
Khin Maung Win
Saeed Hamid
Teerha Piratvisuth
Soek Siam Tan
Yock Young Dan
Yin Mei Lee
Taufique Ahmed
Wei Lyn Yang
Kok Pun Chen
Mrunal Kamat
Manav Wadhawan
Kaushal Madan
Rajiv Mehta
Akash Shukla
Prashant Dhore
Chundamannil E. Eapen
Priya Abraham
Satyendra Tyagi
Abraham Koshy
Aung Hlaing Bwa
Wasim Jafri
Shahab Abid
Fakhar Ali Qazi Arisar
Tewesak Tanwandee
Thing Phee Yin
Hoi Poh Tee
Rosaida Binti Hj Md Said
Khean Lee Goh
Shiaw Hooi Ho
Rosmawati Mohamed
Norasiah Abu Bakar
National University Health System
Khoo Teck Puat Hospital
The Aga Khan University
Yong Loo Lin School of Medicine
Fortis Escorts Heart Institute & Research Centre
University of Malaya Medical Centre
Mahidol University
Prince of Songkla University
Tan Tock Seng Hospital
Lokmanya Tilak Municipal Medical College
Christian Medical College, Vellore
Kailashi Superspeciality Hospital
Yangon GI & Liver Centre
Sime Darby Medical Centre
Surat Institute of Digestive Sciences
Global Hospital Superspeciality and Transplant Center
Hospital Raja Perempuan Zainab II
Lakeshore Hospital
Hospital Ampang
Artemis Health Institute
Hospital Selayang
Hospital Tengku Ampuan Afzan
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Dec-2018
Citation: Journal of Viral Hepatitis. Vol.25, No.12 (2018), 1533-1542
Abstract: © 2018 John Wiley & Sons Ltd There is a paucity of information on chronic hepatitis C (CHC) patients treated with direct antiviral agents (DAAs) in Asia. We invited Asia-Pacific physicians to collate databases of patients enrolled for CHC treatment, recording baseline clinical, virologic and biochemical characteristics, sustained virologic response at week 12 (SVR12) and virologic failure. SVR12 outcome was based on intention to treat (ITT). Multivariate analysis was used to assess independent risk factors for SVR12 using SPSS version 20. A total of 2171 patients from India (n = 977), Myanmar (n = 552), Pakistan (n = 406), Thailand (n = 139), Singapore (n = 72) and Malaysia (n = 25) were collected. At baseline, mean age was 49 years, 50.2% were males, and 41.8% had cirrhosis. Overall, SVR12 was 89.5% and by genotype (GT) based on ITT and treatment completion, respectively, was 91% and 92% for GT1, 100% and 100% for GT2, 91% and 97% for GT3, 64% and 95% for GT4, 87% and 87% for GT6 and 79% and 91% for GT untested. Patients with cirrhosis had SVR12 of 85% vs 93% for noncirrhosis (P < 0.001) (RR 2.1, 95% CI 1.4-3.1, P = 0.0002). Patients with GT1 and GT3 treated with sofosbuvir/ribavirin (SR) had 88% and 89% SVR12, respectively, but those GT6 treated with sofosbuvir/ledipasvir (SL) had only 77.6% SVR12. Multivariate analysis showed absence of cirrhosis was associated with higher SVR12 (OR 2.0, 95% CI 1.3-3.1, P = 0.002). In conclusion, patients with GT1 and GT3 with/without cirrhosis had surprisingly high efficacy using SR, suggesting that Asians may respond better to some DAAs. However, poor GT6 response to SL suggests this regimen is suboptimal for this genotype.
ISSN: 13652893
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.